CHF10196 tablets (florensocatib)

Phase 3

CHF10196 tablets (florensocatib) is one of 36 therapeutic programs targeting Bronchiectasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

BronchiectasisNot yet recruiting

BronchiectasisPhase 3

Not yet recruiting

Competition

Competitive Landscape

76 competitors in Bronchiectasis

#DrugCompanyPhaseTrials

Cipro

Bayer

Approved

1 2

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 3

Tobrex

VViatris Specialty LLC

Approved

2 4

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 5

Garamycin

SSchering-Plough

Approved

1 6

Qvar

Foradil

Osmitrol

BB. Braun Medical Inc.

Phase 3

1 9

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

1 10

Daliresp

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 3Not yet recruiting

Bronchiectasis

NCT07577804

Clinical

Trials by Indication[1]

Bronchiectasis1 trial

A Phase III, Randomised, Double-blind, Two-arm Study to Investigate the Efficacy and Safety of Treatment With CHF10196 Tablets (Florensocatib) Compared With Placebo for up to 78 Weeks, Followed by an Open-label Extension, in Male and Female Participants 12 to 85 Years of Age With Bronchiectasis

Not yet recruiting· Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.·Phase 3·NCT07577804·904 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CHF10196 tablets (florensocatib). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for CHF10196 tablets (florensocatib). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Chiesi Farmaceutici S.p.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Chiesi Farmaceutici S.p.A.

CHF10196 tablets (florensocatib)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Bronchiectasis1 trial

References

Drug Info

Quick Facts

Related News